̽ѡ

Precision pathology and tumor heterogeneity – Johan Hartman's Group

The Hartman research lab performs pioneering research in precision pathology, focusing on personalized breast cancer therapy based on tumor biology. Using advanced diagnostic methods such as digital image analysis, AI, cancer genomics, and patient-derived tumor models, we enhance treatment predictions and risk assessments. Hartman's research group has also developed clinical-grade AI tools for analyzing histopathological images, enabling more accurate and cost-effective diagnostics.

Part of the:
The members of Johan Hartman's group is lined up in front of a house.

Our research

Breast cancer remains to be the most common malignancy for women in Sweden. Great improvements in screening and adjuvant therapy have led to a current 5-year survival rate of 90%. The individual treatment strategy is based on routine biomarkers on immunohistochemical level; estrogen receptor (ER), progesterone receptor (PR), Her2 and Ki67. ER expression confers strong indications for response to endocrine therapy, whereas patients with Her2-overexpressing tumors can be effectively treated with anti-Her2 therapy. However, such management of breast cancer patients is insufficient to distinguish resistant tumors. We use a variety of methods to identify patterns of drug resistance. Our projects are all of translational character and goes from in vitro experimental models to studies on patient material ex vivo. We are also very interested in the role of tumor-metastatic heterogeneity in relation to drug response.

Publications

Selected publications

  • Journal article: LANCET REGIONAL HEALTH-EUROPE. 2024;40:100886
    Acs B; Hartman J; Sönmez D; Lindman H; Johansson ALV; Fredriksson I
  • Article: JOURNAL OF NUCLEAR MEDICINE. 2024;65(5):700-707
    Altena R; af Buren S; Blomgren A; Karlsson E; Tzortzakakis A; Brun N; Moein MM; Jussing E; Frejd FY; Bergh J; Tran TA; Hartman J; Axelsson R
  • Article: SCIENCE. 2023;382(6675):eadf8486
    Engblom C; Thrane K; Lin Q; Andersson A; Toosi H; Chen X; Steiner E; Lu C; Mantovani G; Hagemann-Jensen M; Saarenpaa S; Jangard M; Saez-Rodriguez J; Michaelsson J; Hartman J; Lagergren J; Mold JE; Lundeberg J; Frisen J
  • Article: EUROPEAN JOURNAL OF CANCER. 2023;191:112953
    Wang Y; Ali MA; Vallon-Christersson J; Humphreys K; Hartman J; Rantalainen M
  • Article: NATURE BIOTECHNOLOGY. 2023;41(8):1085-1088
    Llorens-Bobadilla E; Zamboni M; Marklund M; Bhalla N; Chen X; Hartman J; Frisen J; Stahl PL
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Wang Y; Kartasalo K; Weitz P; Ács B; Valkonen M; Larsson C; Ruusuvuori P; Hartman J; Rantalainen M
  • Article: NATURE COMMUNICATIONS. 2023;14(1):982
    Jun S-H; Toosi H; Mold J; Engblom C; Chen X; O'Flanagan C; Hagemann-Jensen M; Sandberg R; Aparicio S; Hartman J; Roth A; Lagergren J
  • Meeting abstract: ANNALS OF ONCOLOGY. 2022;33(7):S1306
    Chen X; Sifakis EG; Robertson S; Neo SY; Jun S-H; Tong L; Lovrot J; Tay A; Hellgren R; Margolin S; Bergh J; Foukakis T; Lagergren J; Lundqvist A; Ma R; Hartman J
  • Article: ANNALS OF ONCOLOGY. 2022;33(1):89-98
    Wang Y; Acs B; Robertson S; Liu B; Solorzano L; Wahlby C; Hartman J; Rantalainen M
  • Article: NATURE BIOMEDICAL ENGINEERING. 2020;4(9):875-888
    Tanaka N; Kanatani S; Kaczynska D; Fukumoto K; Louhivuori L; Mizutani T; Kopper O; Kronqvist P; Robertson S; Lindh C; Kis L; Pronk R; Niwa N; Matsumoto K; Oya M; Miyakawa A; Falk A; Hartman J; Sahlgren C; Clevers H; Uhlen P

Staff and contact

Group leader

All members of the group

Keywords:
Artificial Intelligence Artificial Intelligence Breast Neoplasms Cancer and Oncology Clinical Laboratory Medicine Show all
Content reviewer:
Johan Hartman
Erika Rindsjö
04-06-2025